ImageneBio, Inc. (IMA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ImageneBio, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DP Drew Phillips Fortitude Family Office LLC | 400 | $2,760 | $2,272 | -$488 | -17.68% |
ImageneBio, Inc. (IMA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ImageneBio, Inc. ever had a stock split?
ImageneBio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kristin Yarema CEO | NASDAQ (CM) Exchange | 45175G207 CUSIP |
| US Country | 10 Employees | - Last Dividend | 28 Jul 2025 Last Split | - IPO Date |
Overview
We are a clinical-stage biotechnology company focused on developing innovative therapies aimed at treating a range of immunological, autoimmune, and inflammatory (I&I) diseases. Our mission is to create differentiated treatment options that improve the quality of life for patients suffering from these complex conditions. One of our flagship products, IMG-007, is a non-depleting anti-OX40 monoclonal antibody currently undergoing evaluation in a Phase 2b clinical trial for atopic dermatitis. This therapeutic approach exemplifies our commitment to advancing science in the treatment of challenging health issues.
Products and Services
- IMG-007 (non-depleting anti-OX40 monoclonal antibody)
IMG-007 is our lead product candidate designed specifically to target the OX40 receptor, which plays a critical role in the immune response and is implicated in various I&I diseases. Currently in Phase 2b clinical trials for atopic dermatitis, IMG-007 is developed to alleviate symptoms by modulating immune function without depleting essential immune cells, thereby reducing the risk of systemic immunosuppression. This innovative approach aims to provide a safer and more effective treatment option for patients dealing with chronic inflammatory conditions.
- Research and Development Services
In addition to our proprietary products, we offer extensive research and development services aimed at advancing the understanding and treatment of immunological and autoimmune disorders. Our dedicated R&D team explores novel pathways and therapeutic targets in the field of immunology, collaborating with academic institutions and industry partners to bring innovative therapies to market. We leverage cutting-edge technology and methodologies to drive our research initiatives.
